Skip to content

Clinical trials

Mpox, Monkeypox trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Mpox, Monkeypox Clear all

72 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20081
20171
20181
20191
20202
20212
202215
202313
202411
202515
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed24
Recruiting14
Active, not recruiting9
Unknown status7
Not yet recruiting6
Enrolling by invitation6
Terminated3
Suspended1
Available1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institute of Tropical Medicine, Belgium9
National Institute of Allergy and Infectious Diseases (NIAID)7
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia4
ANRS, Emerging Infectious Diseases3
Assistance Publique - Hôpitaux de Paris3
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"3
Osaka Metropolitan University3
Bavarian Nordic2
BioNTech SE2
Centers for Disease Control and Prevention2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Mpox, Monkeypox72
Smallpox11
Cowpox4
HIV Infections3
Infections3
Poxviridae Infections3
COVID-192
Vaccinia2
Acquired Immunodeficiency Syndrome1
Chikungunya Fever1

Trials

Showing 51 to 72 of 72. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.